Overall, there was a difference of 14.2 MN/1000 (s.e. 2.4; 95% CL 9.3–19.1; P<0.001) between BC patients and controls (subjects without cancer, BRCA negatives and with negative FH for BC). The gene discussed is FH; the disease is cancer.